Click here for the full article
Please click here to see the article
Validation of Keratin 17 as a tissue biomarker in the diagnosis of upper tract urothelial carcinoma
February 28, 2025
Please click here to view the story
EmeritusDX and KDx Diagnostics Inc. Announce a Partnership to Offer the URO17 NON-INVASIVE Urine Test for Bladder Cancer
November 10, 2022
IRVINE, CALIF., AND SAN JOSE, CALIF. (PRWEB) NOVEMBER 07, 2022 EmeritusDX and KDx Diagnostics announced today the partnership to provide the URO17 test for the detection of bladder cancer. URO17 is a non-invasive urine test with high sensitivity and negative predicted value (NPV) that can be used to determine the status of active bladder cancer...
KDx Diagnostics And Lister Hospital Announce The Launch Of A Non-Invasive URO17® Urine Test For Bladder Cancer In The United Kingdom
December 7, 2021
SAN JOSE, Calif. and STEVENAGE, England, Dec. 5, 2021 /PRNewswire/ — KDx Diagnostics, Inc. (KDx), and Lister Hospital (East and North Hertfordshire NHS Trust), Stevenage, UK, announced today the launch in the United Kingdom (UK) of KDx’s URO17® test for detection of bladder cancer. This non-invasive urine test for bladder cancer is highly sensitive for identifying...
By Daniel Dunaief Detectives often look for the smallest clue that links a culprit to a crime. A fingerprint on the frame of a stolen Picasso painting, a shoe print from a outside a window of a house that was robbed or a blood sample can provide the kind of forensic evidence that helps police...
A revolutionary new urine screening test that utilizes a novel Keratin 17 (K17) cancer biomarker can detect the presence of new bladder cancer in patients with hematuria, or blood in the urine, according to a study led by researchers at Yale Cancer Center, Stony Brook University, and KDx Diagnostics, Inc. The findings also show the test can detect...
KDx Diagnostics, Cardiff University, Cardiff and Vale University Health Board and Cellpath announce
June 3, 2021
CAMPBELL, Calif. and CARDIFF, Wales, May 18, 2021 /PRNewswire/ — KDx Diagnostics, Inc. (KDx), Clinical Innovation Accelerator (CIA), Cardiff University, Cardiff and Vale University Health Board C&VUHB) and CellPath, announced today a partnership to develop a non-invasive urine test for suspected bladder cancer patients through the Accelerate programme. KDx Diagnostics Inc., located in Campbell, CA,...
URO17 For Detecting Bladder Cancer
February 4, 2021
URO17 is a urine test for detecting bladder cancer in people with symptoms associated with malignancy, including blood in the urine (haematuria) or lower urinary tract symptoms. It is also indicated for detecting urogenital cancer recurrence in the urogenital tract during treatment follow up. URO17 is an immunocytochemistry-based test that detects the presence of the...
07/03/20 KDx Diagnostics Announces CE Marking for Innovative Non-invasive URO17™ Bladder Cancer Test
July 26, 2020
KDx Diagnostics, Inc., announced today that it has received Conformité Européene (CE) Marking for its innovative and proprietary urine-based test (the URO17™ test) for bladder cancer … Read More
© 2025 KDx Diagnostics Inc.